Femara (Letrozole) for Fertility: HSA/FSA Eligibility, Submission, and How to Pay Less

Is Letrozole for Fertility an HSA or FSA Eligible Expense?

Yes. Letrozole prescribed specifically to induce ovulation or support fertility treatment is a qualified medical expense under IRS Publication 502, which governs HSA and FSA reimbursements. The IRS defines qualified medical expenses as costs for the diagnosis, cure, mitigation, treatment, or prevention of disease. Infertility treatment, including ovulation-induction medications, falls within that definition.

The catch is documentation. Some HSA and FSA administrators flag letrozole because it is also used for breast cancer treatment in postmenopausal women (its original FDA-approved indication), and off-label fertility use is not printed on the FDA label. Your administrator may ask you to prove the prescription is for fertility. That proof comes in two forms: the prescription itself (which shows your diagnosis code if your pharmacy transmits it) or a Letter of Medical Necessity from your prescriber.

What the IRS Actually Says

IRS Publication 502 lists "fertility enhancement" as a deductible medical expense, including procedures and medications used to overcome inability to have children. Ovulation-induction drugs are specifically called out. This means letrozole for PCOS-related anovulation, unexplained infertility, or other diagnosed fertility conditions qualifies.

What Your Plan Administrator May Require

Most major HSA custodians (Fidelity, HSA Bank, HealthEquity) and FSA third-party administrators auto-approve a pharmacy receipt showing a prescription drug with an NDC code. A minority of plans require an LMN if the drug has non-fertility uses. Always save your pharmacy receipt showing the drug name, date, amount, and your name. That is your primary documentation.

PCOS as a Qualifying Diagnosis

For women with PCOS, letrozole is the first-line ovulation induction agent per the 2023 international evidence-based PCOS guideline, which specifically recommends letrozole over clomiphene based on higher live-birth rates. Because PCOS is a diagnosed condition with ICD-10 code E28.2, a prescription written under that code leaves no ambiguity for your HSA or FSA administrator.

How to Submit Letrozole to Your HSA or FSA

Submitting is straightforward when you follow the right order of steps. Getting the paperwork wrong delays reimbursement by weeks.

Step 1: Get a Written Prescription with Diagnosis Code

Ask your OB-GYN, reproductive endocrinologist, or NP to include the ICD-10 diagnosis code on the prescription or in the office notes. Common codes for fertility indications include:

• E28.2 (polycystic ovarian syndrome)
• N97.0 (female infertility due to anovulation)
• N97.9 (female infertility, unspecified)
• Z31.61 (encounter for female fertility testing)

Step 2: Fill the Prescription at a Participating Pharmacy

Use your health plan's in-network pharmacy if you have one. The pharmacy receipt or explanation of benefits (EOB) from your insurer serves as the primary submission document. If you pay out of pocket (common when insurance does not cover fertility drugs), the itemized pharmacy receipt is sufficient.

Step 3: Submit via Your Administrator's Portal or App

Log into your HSA bank or FSA administrator portal. Upload:

1. Itemized pharmacy receipt or EOB
2. LMN (only if your specific plan requires it for letrozole)

Most administrators process approved fertility drug claims within 3 to 5 business days. Rejected claims are almost always missing the prescription documentation or submitted with a grocery-store receipt rather than an itemized pharmacy receipt.

Step 4: If Your Claim Is Denied, Appeal With an LMN

If your plan denies the claim, do not simply resubmit the same documents. Request an LMN template from your administrator. Your provider fills it out, signs it, and states: the diagnosis, why letrozole is medically necessary for your fertility treatment, and the expected treatment period. An LMN overturns the majority of initial denials for fertility medications.

The WomanRx "Document Before You Dispense" framework: confirm HSA/FSA eligibility with your administrator before your prescription is filled, not after. A two-minute call or chat to your plan saves weeks of appeals. Ask specifically: "Is letrozole for ovulation induction covered under my FSA? Do you need an LMN?" Get the answer in writing (screenshot the chat or request an email confirmation).

How to Get Letrozole for Fertility Cheaper

Generic letrozole is already one of the least expensive fertility medications available. A 5-day course of 2.5 mg tablets costs as little as $8 to $12 at cost-plus pharmacies, and rarely more than $50 even at full retail price at chain pharmacies. Still, costs add up across multiple cycles, and here are the most reliable ways to reduce what you pay.

Generic vs. Brand (Femara)

Brand-name Femara is no longer commonly used for fertility because the generic is bioequivalent and costs a fraction of the price. Novartis's original Femara patent expired, and multiple generic manufacturers now produce letrozole. There is no clinical reason to pay for brand Femara for fertility purposes. Ask your pharmacy to confirm they are dispensing the generic (letrozole), not the brand.

GoodRx and Similar Discount Cards

GoodRx, RxSaver, and NeedyMeds coupons can reduce letrozole to under $15 for a 5-day supply at most major chains. These coupons cannot be combined with insurance, but if your insurance does not cover fertility drugs (many employer plans exclude them), a discount card is often cheaper than running it through insurance.

You cannot use an HSA or FSA card at the point of sale if you also use a GoodRx coupon at that transaction. However, you can pay with GoodRx at the pharmacy counter, then submit the itemized receipt to your HSA or FSA for reimbursement. The reimbursement is still allowed because you are being reimbursed for a qualified medical expense, regardless of what discount you used to purchase it.

Cost-Plus Pharmacies

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) offers letrozole 2.5 mg for under $10 for a typical 5-tablet course. You pay the listed price plus a dispensing fee and shipping. The itemized receipt from Cost Plus Drugs is HSA/FSA-reimbursable the same way any pharmacy receipt is.

Manufacturer and Nonprofit Assistance

Because letrozole is generic, Novartis no longer offers a Femara coupon card for fertility patients. However, reproductive-medicine nonprofits offer medication assistance for fertility drugs, including letrozole:

• RESOLVE: The National Infertility Association maintains a medication-assistance directory at resolve.org.
• Baby Quest Foundation provides grants covering fertility medications.

Income eligibility and cycle-timing requirements vary by program. Apply at least 4 to 6 weeks before your anticipated cycle start.

Telehealth Prescriptions and Bundled Care

Some women's-health telehealth platforms, including WomanRx, bundle the monitoring visit, prescription, and pharmacy discount into a single flat-fee package for ovulation-induction cycles. This removes the separate lab, ultrasound, and medication billing that makes traditional fertility clinic cycles expensive. Confirm whether the telehealth visit fee itself is HSA/FSA eligible (it is, when the visit is for diagnosis and treatment of a medical condition).

What Letrozole Actually Does: A Quick Clinical Primer for the Woman Paying for It

Understanding why you are taking letrozole helps you advocate for the right dose and cycle monitoring, which affects how many cycles you need and therefore how much you spend overall.

Letrozole is an aromatase inhibitor. It works by temporarily blocking estrogen production, which causes your pituitary gland to release more FSH (follicle-stimulating hormone). That FSH surge recruits follicles and drives ovulation. Because the estrogen suppression is transient, letrozole does not have the anti-estrogenic effect on the uterine lining that clomiphene (Clomid) can cause. This makes letrozole the preferred agent for ovulation induction in most guidelines.

Dosing Across the Cycle

The standard starting dose is 2.5 mg daily for 5 days, typically taken on cycle days 3 through 7 or cycle days 5 through 9. Your provider may increase the dose to 5 mg or 7.5 mg daily if follicular response is inadequate in a prior cycle. The dose increase happens in 2.5 mg increments.

Women with PCOS tend to respond at lower doses than women with unexplained infertility or diminished ovarian reserve. Women with a higher BMI (above 30 kg/m²) may need a higher starting dose because adipose tissue converts androgens to estrogen via aromatase, which partially blunts letrozole's FSH-stimulating effect.

Effectiveness Data

A landmark NICHD-funded multicenter trial published in the New England Journal of Medicine (the PPCOS II trial) found that letrozole produced a cumulative live-birth rate of 27.5% versus 19.1% for clomiphene over up to five treatment cycles in women with PCOS. This is the most-cited head-to-head fertility trial in women with PCOS and is the reason ASRM and the international PCOS guidelines recommend letrozole as first-line therapy.

For women with unexplained infertility, the AMIGOS trial found comparable pregnancy rates between letrozole and clomiphene when combined with intrauterine insemination (IUI), though letrozole produced fewer high-order multiple pregnancies, which is a safety advantage. The AMIGOS trial results were published in the New England Journal of Medicine in 2015.

Pregnancy, Lactation, and Contraception Safety

Letrozole is contraindicated during established pregnancy. This is the most important safety point for any woman using letrozole for fertility. You take letrozole in the follicular phase, before ovulation, and stop before implantation occurs. If you have a positive pregnancy test, do not take letrozole.

Pregnancy Category and Human Data

Letrozole does not have an FDA pregnancy category under the current labeling system (categories were replaced in 2015 by the Pregnancy and Lactation Labeling Rule, PLLR). Under PLLR, the letrozole prescribing information states that animal studies show embryo-fetal toxicity and teratogenicity at doses near the human therapeutic dose. Human data from fertility use has not demonstrated a statistically significant increase in major congenital malformations compared to the general population, based on a 2012 analysis of over 900 letrozole-exposed pregnancies published in Fertility and Sterility. Earlier concerns about cardiac defects were not confirmed in larger subsequent studies.

The FDA prescribing information for letrozole states the drug can cause fetal harm. For fertility patients, this means the timing protocol (taking letrozole only in the follicular phase and stopping before ovulation) is what makes it safe in practice.

Lactation

Letrozole is used in postmenopausal women for breast cancer suppression, where lactation is not a consideration. Data on letrozole transfer into human breast milk are extremely limited. Given the drug's mechanism (suppressing estrogen) and its potential effects on infant development, letrozole should not be used while breastfeeding. Women in the postpartum period who are considering fertility treatment should discuss timing with their provider, as ovulation typically does not resume at predictable intervals while fully breastfeeding.

Contraception Requirement

Because letrozole is used to achieve pregnancy, not to prevent it, a formal contraception requirement does not apply in the same way as it does for teratogens like isotretinoin. However, women who are prescribed letrozole for non-fertility indications (for example, off-label use for endometriosis suppression) and who do not want to conceive must use effective contraception, because letrozole can paradoxically trigger ovulation in premenopausal women even when used for suppression.

Evidence Gap Disclosure

Most letrozole fertility safety data comes from women with PCOS in their 20s and 30s. Data in women over 40 using letrozole for diminished ovarian reserve, and data specifically in the perimenopause-adjacent population with irregular cycles, are extrapolated from smaller case series rather than randomized trials. If you are over 38 and pursuing letrozole cycles, ask your provider whether the existing trial data applies directly to your situation.

Who Letrozole for Fertility Is and Is Not Right For

Women Most Likely to Benefit

Reproductive years with PCOS and anovulation. This is the best-studied group. Letrozole is first-line therapy, supported by the PPCOS II trial, ASRM practice guidelines, and the 2023 international PCOS guideline.

Women with unexplained infertility using IUI. Letrozole combined with IUI is a reasonable first-line approach before moving to injectable gonadotropins.

Women with a history of poor uterine lining on clomiphene. Because letrozole does not block estrogen receptors in the endometrium (unlike clomiphene), lining thickness is generally better preserved.

Women who want to minimize multiple-pregnancy risk. Letrozole carries a lower multiple-gestation rate than injectable gonadotropins and comparable rates to clomiphene.

Women for Whom Letrozole May Not Be the Right Choice

Women with premature ovarian insufficiency (POI). If your ovaries are not producing eggs, ovulation induction cannot help. FSH levels above 40 IU/L on cycle day 3 suggest POI rather than anovulation, and the approach shifts entirely.

Women with severe tubal factor or male-factor infertility requiring IVF. Letrozole can be used in IVF as a mild-stimulation protocol, but it is not a substitute for IVF when anatomy or severe sperm abnormalities are the primary barrier.

Women currently pregnant or breastfeeding. See the pregnancy and lactation section above.

Perimenopause. Letrozole is approved for postmenopausal breast cancer treatment, which reflects its mechanism. In perimenopause, cycles are irregular and ovarian reserve is declining. If you are perimenopausal and pursuing fertility treatment, a reproductive endocrinologist should evaluate whether letrozole cycles or assisted reproductive technology is the more appropriate path before you spend money on repeated letrozole cycles with low probability of success.

Life-Stage Summary: Letrozole for Fertility Across Reproductive Years

Letrozole's role differs meaningfully depending on where you are hormonally.

Ages 18 to 35 with PCOS: Strongest evidence base. Start at 2.5 mg, monitor with cycle day 12 to 14 ultrasound to confirm follicular response and reduce multiple-pregnancy risk.

Ages 35 to 40 with unexplained infertility or mild ovarian reserve decline: Letrozole plus IUI remains reasonable for up to three cycles before escalating to IVF, per ASRM practice guidelines. Antral follicle count and AMH should guide the decision.

Ages 40 and older: Success rates with oral ovulation induction drop significantly. A reproductive endocrinologist visit before starting letrozole cycles is worth the investment, because jumping directly to IVF may save time and money overall for many women in this age group.

Postpartum (trying to conceive again): If you had PCOS before pregnancy, it does not resolve postpartum. Letrozole cycles can resume once you have had two to three normal menstrual cycles, typically 6 to 12 months after delivery if not fully breastfeeding.

HSA and FSA Strategy for Multi-Cycle Letrozole Treatment

If your provider anticipates three to five letrozole cycles (a common treatment plan), plan your HSA or FSA contributions accordingly. You can contribute up to $4,300 to an HSA for self-only coverage in 2026 or up to $8,550 for family coverage. FSA limits for 2026 are set by your employer but are capped by the IRS at $3,300 for health FSAs.

A five-cycle letrozole course at $30 per cycle is only $150. The bigger HSA and FSA expenses in a letrozole monitoring cycle are the cycle-day 3 labs (FSH, estradiol, AMH if not recently checked), the mid-cycle ultrasound to confirm follicular response, and the office visit. All of these are HSA and FSA eligible when prescribed for a diagnosed medical condition. Budget $300 to $800 per monitored cycle for the full picture, depending on your clinic and geography.

If you have an FSA with a "use it or lose it" deadline approaching, letrozole and associated monitoring costs are a good use of remaining funds because they are predictably timed to your menstrual cycle. You can schedule an ovulation-induction cycle intentionally near your FSA deadline if you are already planning to try.